Abatacept or tocilizumab after rituximab in rheumatoid arthritis? An exploratory study suggests non-response to rituximab is associated with persistently high IL-6 and better clinical response to IL-6 blocking therapy

Das, S, Vital, EM, Horton, S, Bryer, D, El-Sherbiny, Y ORCID logoORCID: https://orcid.org/0000-0003-4791-3475, Rawstron, AC, Ponchel, F, Emery, P and Buch, MH, 2014. Abatacept or tocilizumab after rituximab in rheumatoid arthritis? An exploratory study suggests non-response to rituximab is associated with persistently high IL-6 and better clinical response to IL-6 blocking therapy. Annals of the Rheumatic Diseases, 73 (5), pp. 909-912. ISSN 0003-4967

Full text not available from this repository.
Item Type: Journal article
Publication Title: Annals of the Rheumatic Diseases
Creators: Das, S., Vital, E.M., Horton, S., Bryer, D., El-Sherbiny, Y., Rawstron, A.C., Ponchel, F., Emery, P. and Buch, M.H.
Publisher: BMJ
Date: 2014
Volume: 73
Number: 5
ISSN: 0003-4967
Identifiers:
Number
Type
10.1136/annrheumdis-2013-204417
DOI
1199943
Other
Divisions: Schools > School of Science and Technology
Record created by: Linda Sullivan
Date Added: 14 Oct 2019 14:51
Last Modified: 14 Oct 2019 14:51
URI: https://irep.ntu.ac.uk/id/eprint/37954

Actions (login required)

Edit View Edit View

Statistics

Views

Views per month over past year

Downloads

Downloads per month over past year